Compare Amylx Pharmaceuticals Inc (AMLX) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Mercadolibre Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.6 (market cap $2.64B), while Mercadolibre Inc trades at $1,876.89 (market cap $98.35B). The key difference: Mercadolibre Inc is far larger — about 37.3× Amylx Pharmaceuticals Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Amylx Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | MELI | |
|---|---|---|
Market Cap | $2.64B | $98.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $2.51K |
52-Week Low | $7.82 | $1.55K |
Enterprise Value | $2.39B | $106.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
MercadoLibre (MELI) trades at $1,824.34, up 0.2% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $9.19, beating estimates by 6.2%, while revenue grew 50% year-over-year. Operating cash flow reached $12.12 billion in 2025, supporting aggressive growth investments. Analyst consensus remains strongly bullish with a $2,150 price target, though margin compression from strategic spending presents near-term headwinds.
MELI's growth-first strategy drives market share gains but pressures profitability, with net margin declining to 5.3%. The stock offers 18% upside to consensus target but faces execution risk in balancing expansion with returns. Competitive threats from global e-commerce players and Latin American economic volatility require monitoring. Long-term prospects remain positive given ecosystem strength and dominant market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
